130 related articles for article (PubMed ID: 38423674)
41. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Paiva-Oliveira DI; Martins-Neves SR; Abrunhosa AJ; Fontes-Ribeiro C; Gomes CMF
Cancer Chemother Pharmacol; 2018 Jan; 81(1):49-63. PubMed ID: 29086064
[TBL] [Abstract][Full Text] [Related]
43. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
44. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
[TBL] [Abstract][Full Text] [Related]
45. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
46. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression.
Zeng F; Li Y; Meng Y; Sun H; He Y; Yin M; Chen X; Deng G
Exp Mol Med; 2023 Feb; 55(2):364-376. PubMed ID: 36720918
[TBL] [Abstract][Full Text] [Related]
47. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
48. Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition.
Kubista B; Schoefl T; Mayr L; van Schoonhoven S; Heffeter P; Windhager R; Keppler BK; Berger W
J Exp Clin Cancer Res; 2017 Apr; 36(1):52. PubMed ID: 28403890
[TBL] [Abstract][Full Text] [Related]
49. Tranilast enhances the effect of anticancer agents in osteosarcoma.
Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
[TBL] [Abstract][Full Text] [Related]
50. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
51. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
52. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
53. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Fehling SC; Miller AL; Garcia PL; Vance RB; Yoon KJ
Cancer Lett; 2020 Jan; 468():48-58. PubMed ID: 31605774
[TBL] [Abstract][Full Text] [Related]
54. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
55. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
[TBL] [Abstract][Full Text] [Related]
56. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
[TBL] [Abstract][Full Text] [Related]
57. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
59. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
60. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
Yang CY; Qin C; Bai L; Wang S
Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]